Viridian Reports Positive Phase 3 Results in Thyroid Eye
Viridian’s Elegrobart Succeeds in Phase 3 Thyroid Eye Disease Trial In a significant breakthrough for patients with Thyroid Eye Disease (TED), Viridian Therapeutics has announced positive topline results from its pivotal Phase 3 REVEAL1 clinical trial. The trial evaluated the efficacy and safety of elegrobart, the company’s novel investigational monoclonal antibody, in treating active, moderate-to-severe […]
Viridian Reports Positive Phase 3 Results in Thyroid Eye Read More »








